Result of AGM
EDX Medical Group plc announced the results of its Annual General Meeting, where all thirteen resolutions were passed. Resolutions 1 through 11, including the approval of the Annual Report and Accounts for the year ended March 31, 2026, the Remuneration Committee Report, the Directors' Remuneration Policy, the re-appointment of directors Jason Holt, Dr. Michael Hudson, Professor Sir Christopher Evans, Professor Trevor Jones, and Martin Walton, the re-appointment of auditor PKF Littlejohn LLP, and the authorization for directors to determine auditor fees and allot shares, all received overwhelming support with over 99.99% of votes cast in favour. Special resolutions 12 and 13, concerning the disapplication of statutory pre-emption rights, were also passed with significant majorities of 99.66% and 99.69% respectively. As of September 28, 2026, the company had 431,373,146 ordinary shares in issue.
Select text to share a quote on X · sign in to keep highlights & notes in your EDX notes
CAMBRIDGE, UK: EDX Medical (TIDM: EDX), which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, today announces the results of its Annual General Meeting, held at the Henrietta Room, 1 Wimpole Street, London, W1G 0AE on 28 September 2026 at 2.00 p.m.
All resolutions were passed as a poll. Resolutions 1 - 11 were passed as ordinary resolutions and resolutions 12 and 13 were passed as special resolutions.
| Resolution | Votes for | % | Votes against | % | Votes withheld |
|---|---|---|---|---|---|
| Resolution 1 (Ordinary) To receive the Annual Report and Accounts of the Company for the year ended 31 March 2026 together with the Directorsʼ reports and auditorʼs report on those accounts. | 181,843,821 | 100.00 | 0 | 0 | 7,720,023 |
| Resolution 2 (Ordinary) To accept the Remuneration Committee Report for the financial year ended 31 March 2026, as set out in the Company's Annual Report and Accounts for the year ended 31 March 2026. | 181,841,341 | >99.99 | 2,480 | <0.01 | 7,720,023 |
| Resolution 3 (Ordinary) To accept the Directorsʼ Remuneration Policy, as set out in the Company's Annual Report and Accounts for the year ended 31 March 2026. | 169,927,624 | >99.99 | 2,459 | <0.01 | 19,633,761 |
| Resolution 4 (Ordinary) To re-appoint Jason Holt as a director of the Company. | 181,840,525 | >99.99 | 2,517 | <0.01 | 7,720,802 |
| Resolution 5 (Ordinary) To re-appoint Dr Michael Hudson as a director of the Company. | 181,841,125 | >99.99 | 2,433 | <0.01 | 7,720,286 |
| Resolution 6 (Ordinary) To re-appoint Professor Sir Christopher Evans as a director of the Company. | 181,841,143 | >99.99 | 2,433 | <0.01 | 7,720,268 |
| Resolution 7 (Ordinary) To re-appoint Professor Trevor Jones as a director of the Company. | 181,841,085 | >99.99 | 2,473 | <0.01 | 7,720,286 |
| Resolution 8 (Ordinary) To re-appoint Martin Walton as a director of the Company. | 181,841,085 | >99.99 | 2,473 | <0.01 | 7,720,286 |
| Resolution 9 (Ordinary) To re-appoint PKF Littlejohn LLP as auditor of the Company. | 181,839,576 | 100.00 | 0 | 0 | 7,724,268 |
| Resolution 10 (Ordinary) To authorise the Directors to determine the fees payable to the auditor | 181,839,494 | >99.99 | 82 | <0.01 | 7,724,268 |
| Resolution 11 (Ordinary) To authorise the Directors to allot shares in the Company. | 181,818,769 | 99.99 | 19,273 | 0.01 | 7,725,802 |
| Resolution 12 (Special) To disapply statutory pre-emption rights generally. | 181,229,094 | 99.66 | 609,421 | 0.34 | 7,725,329 |
| Resolution 13 (Special) To disapply statutory pre-emption rights pursuant to an acquisition or other capital investment. | 181,080,100 | 99.69 | 567,026 | 0.31 | 7,916,718 |
As at 28 September 2026, there were 431,373,146 ordinary shares in issue with no shares held in treasury, resulting in total voting rights of 431,373,146. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.